Prostate Cancer Researchers Begin Clinical Trial to Evaluate Cancer-Fighting Drug Therapy Skip to main content Close Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Menu Close Call 1-800-CEDARS-1 toggle search form Close 16 May 2013 01:00 AM America/Los_Angeles Prostate Cancer Researchers Begin Clinical Trial to Evaluate Cancer-Fighting Drug Therapy Patients with advanced metastatic prostate cancer and poor prognoses are focus of new Cedars-Sinai study Los Angeles - May 16, 2013 - Researchers at Cedars-Sinai have launched a new clinical trial to investigate the effects of a cancer-fighting drug therapy that has shown favorable outcomes in patients with advanced metastatic prostate cancer. Doctors in the Samuel Oschin Comprehensive Cancer Institute are studying the impact of cabozantinib (XL184) in men with prostate cancer that is resistant to medical and surgical treatments and has spread to other parts of their bodies, including the liver or lungs. Physicians and research scientists are examining the development of the disease among men excluded from other ongoing clinical trials because of the severity of their illnesses. Cabozantinib inhibits various molecular signals, stemming the spread of cancer by killing tumor cells while blocking their escape pathways. It has been shown in early clinical trials to have an effect on men with the metastatic form of prostate cancer – both before and after chemotherapy – by reducing pain and improving bone scans. Cancer researchers believe the new clinical trial of the drug offers an opportunity to make important scientific discoveries for treating the severest forms of prostate cancer, the second leading cause of cancer death among American men and a leading cause of cancer mortality worldwide. "Given the results of previous clinical trials, these patients represent a population that could benefit from the therapy," said Edwin M. Posadas, MD, medical director of the Urologic Oncology Program at the Samuel Oschin Comprehensive Cancer Institute and the lead investigator of the new study. The Cedars-Sinai clinical trial will involve up to 40 adult patients who will all receive cabozantinib. During the first three cycles, patients will be evaluated twice per month so that doctors can adjust dosages. Participants will undergo imaging tests every two months to track their cancers. Patients can continue treatment for as long as they are receiving a benefit. The FDA-approved clinical trial will allow physicians and scientists to focus on a blood- and tissue-based analysis of disease markers that will provide insight into how cabozantinib (XL184) works in patients with this specific type of cancer and other cancers as well. Exelixis Inc. is providing cabozantinib (XL184) for the clinical trial but not contributing any other money or resources to the study. Posadas does not have any financial or proprietary relationships with the company. For more information on urologic oncology clinical trials at Cedars-Sinai, please visit http://cancertrialinfo.csmc.edu or contact Amy Oppenheim, clinical research coordinator, at 310-423- 3713 or [email protected]. Share this release Prostate Cancer Researchers Begin Clinical Trial to Evaluate Cancer-Fighting Drug Therapy Share on: Twitter Share on: Facebook Share on: LinkedIn Search Our Newsroom Social media Visit our Facebook page (opens in new window) Follow us on Twitter (opens in new window) Visit our Youtube profile (opens in new window) (opens in new window) Latest news 07 Oct 2022 - HealthDay: Black Women Less Likely to Get Laparoscopic Fibroid Surgeries 07 Oct 2022 - Faculty Publications: Sept. 29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Booster? Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics 04 Oct 2022 - Cedars-Sinai Showcases Hispanic and Latinx Art Newsroom Home